原始出處紀錄
決策級臨床試驗登錄異動
Aardvark 暫停 ARD-101 在 PWS 的 Phase 3 HERO 試驗
該公司自願暫停 Phase 3 HERO 及 OLE 試驗的招募與給藥，因在健康志願者研究中觀察到可逆的心臟發現。公司正與 FDA 合作確定下一步，並預計在 2026 年第二季提供進一步指引。ARD-201 的開發亦已暫停。
關鍵事實
來源摘錄
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.